More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$147821836
EPS
-1.31
P/E ratio
--
Price to sales
0.46
Dividend yield
--
Beta
1.516051
Previous close
$5.63
Today's open
$5.58
Day's range
$5.52 - $5.73
52 week range
$5.05 - $7.67
show more
CEO
Kevin R.M. Smith
Employees
753
Headquarters
Beverly, MA
Exchange
Nasdaq Global Select
Shares outstanding
26002082
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Inogen, Inc. (INGN) Q3 2026 Earnings Call Transcript
Inogen, Inc. ( INGN ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Lorna Williams - Senior Vice President of Investor Relations Andrew Reding - President, CEO & Director Jason Richardson - CFO, Executive VP & Treasurer Presentation Operator Welcome to Inogen's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, November -- as a reminder, this conference is being recorded today, November 5, 2026.
Seeking Alpha • Nov 6, 2026

What Inogen (INGN) Said on Its Q3 Earnings Call
Inogen NASDAQ: INGN reported lower third-quarter revenue as weaker spending by large European customers offset a return to growth in U.S. sales. The respiratory care company also outlined a $20 million annualized cost-reduction program following the sale of its U.S. oxygen rental business.
MarketBeat • Nov 6, 2026

Inogen Announces Third Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Appoints Andy Reding as President and Chief Executive Officer; Company initiates a $20 million cost reduction program to accelerate profitability.
Business Wire • Nov 5, 2026

Inogen Announces Leadership Transition
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Leadership Transition; Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer.
Business Wire • Nov 5, 2026

Inogen: Cheap Enough To Take A Chance On
Inogen, Inc. (INGN) is upgraded to Buy, driven by operational improvement with support from a robust balance sheet. INGN's $45m share buyback, debt-free status, and cash/investments covering ~61% of market cap provide downside protection and acquisition appeal. Management turnover and anemic 2026 revenue growth guidance (3% at midpoint) remain risks, but operational improvements are emerging.
Seeking Alpha • Oct 20, 2026

Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.
Business Wire • Oct 15, 2026

Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
Business Wire • Sep 30, 2026

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Zacks Investment Research • Aug 21, 2026

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks Investment Research • Aug 11, 2026

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks Investment Research • Aug 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Inogen Inc commission-free¹. Build wealth for the long term using automated trading and transfers.